
Novo Nordisk Pharmatech and Novozymes have partnered up to developed specialty enzymes meant for biopharma processing and regenerative medicines, the firms announce in a shared press release.
The enzymes will be focused on stem cell and gene therapies in particular.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app